TOTAL VOLUME:

$154.7b

24H VOL:

$279,496,801

24H TRANSACTIONS:

2,984,640,614

OPEN INTEREST:

$1,923,931,766

416,910

Markets across

40,107

events

MATCHED EVENTS:

4,571

PLATFORM COVERAGE:

5

Polymarket:

37%

VS.

Kalshi:

63%

BETA
Dashboards
Insights
Indices
API
Tour
All
Trending
Breaking
New
Ending Soon
Politics
Sports
Elections
Crypto
Companies
Financials
Economics
Other
Entertainment
Science and Technology
Will Theravance Biopharma (TBPH) beat quarterly earnings?
polymarket

Will Theravance Biopharma (TBPH) beat quarterly earnings?

Oct 26, 2026, 8:08 PM EST - Nov 9, 2026, 4:00 PM EST
Total volume:
$964
Volume 24h:
$0N/A
Liquidity:
$995
30%
Open interest:
$585N/A

Will Theravance Biopharma (TBPH) beat quarterly earnings?

 - Polymarket

Will Theravance Biopharma (TBPH) beat quarterly earnings? - Polymarket

1W

News

Positive

Negative

Neutral

Hover marker for details

Vol.

·

Resolves Nov 9, 2026

Time left: 06d:16h:01m

Will Theravance Biopharma (TBPH) beat quarterly earnings?

7%chance
Amount

$

Trade on
polymarket

Trade on Polymarket

At 9.1¢ buys you 1,099 shares | Odds: 7% Total Payout: $1,099 | Net Profit: $999 Multiplier: 10.99x | ROI: 999% APY not meaningful Low liquidity 6 days to resolution
You will be redirected to the platform to complete this trade.
Outcome
Trade
Chance %
Price
Spread
Liquidity
Volume
24h
7d
Open Interest
Ends in
Result
polymarket

Will Theravance Biopharma (TBPH) beat quarterly earnings?

Trade
7%
Yes 9.1¢No 96¢
5.1¢
$995
$964
0%
2,634%
N/A
6d 16h 1m
Active
Total markets: 1

Description

As of market creation, Theravance Biopharma is estimated to release earnings on November 9, 2026. The Street consensus estimate for Theravance Biopharma's GAAP EPS for the relevant quarter is $0.18 as of market creation. This market will resolve to "Yes" if Theravance Biopharma reports GAAP EPS greater than $0.18 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents. If Theravance Biopharma releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”. If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets reflect the selected street consensus estimate for GAAP EPS as of market creation. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.

Polymarket

As of market creation, Theravance Biopharma is estimated to release earnings on November 9, 2026. The Street consensus estimate for Theravance Biopharma's GAAP EPS for the relevant quarter is $0.18 as of market creation. This market will resolve to "Yes" if Theravance Biopharma reports GAAP EPS greater than $0.18 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents. If Theravance Biopharma releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”. If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets reflect the selected street consensus estimate for GAAP EPS as of market creation. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.

Frequently asked questions

On Polymarket, the dashboard for the Theravance earnings market tracks the current odds of Theravance Biopharma beating quarterly earnings expectations. You can view the probability of the 'yes' outcome, the total volume traded, and the 24-hour volume, providing insights into market activity. The dashboard also displays the price history, allowing you to analyze how the market has moved over time. Currently, the volume is $964 and the 24-hour volume is $69, indicating the level of interest in this particular market.

Currently, the prediction market suggests a 6.6% chance that Theravance Biopharma will beat quarterly earnings. This contrasts with traditional analyst forecasts, which represent a centralized view. It’s common to see discrepancies between prediction market probabilities and those derived from polls or analyst reports, as this market aggregates diverse opinions and allows traders to weigh information dynamically. The collective wisdom of the crowd often provides a unique perspective on the likelihood of this event occurring, potentially reflecting information not yet incorporated into standard financial models.

On Polymarket, this market is priced through a continuous exchange mechanism where traders buy and sell shares representing their belief about whether Theravance Biopharma will beat quarterly earnings. The price of these shares fluctuates based on supply and demand, reflecting the collective sentiment of the market participants. On Polymarket, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. The closer the earnings announcement date, the more responsive the price will be to new information and breaking news related to the company's performance and expectations. The current price reflects the market's best estimate of the probability of a positive earnings surprise.

This market resolves around Nov 9, 2026, with the outcome confirmed once the event is verifiable from credible public reporting. Resolution will be based on whether Theravance Biopharma’s reported earnings per share (EPS) exceed the consensus estimate of financial analysts covering the company. The final market outcome will reflect whether the company delivered a positive earnings surprise, as determined by comparing the actual EPS to the expected EPS. Traders will be able to claim their winnings or settle their losing positions following the official announcement and verification of the results.

Several signals could significantly impact this market. Any news regarding Theravance Biopharma's performance, such as pre-earnings announcements, changes in analyst ratings, or updates on key drug development programs, could cause the odds to shift. Broader market trends and overall economic conditions can also play a role, as investor sentiment can influence trading activity. Unexpected news about competitors or the pharmaceutical industry as a whole could also move this market. Monitoring these factors will be crucial for understanding potential price movements before Nov 9, 2026.